Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States

Urology

Volumn 51, Issue 2, 1998, Pages 186-195

  Orozco, Roberto ^a   O'Dowd, Gerard ^a   Kunnel, Binitha ^a   Miller, M Craig ^a   Veltri, Robert W ^a  

^a UroCor Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PRIVATE PRACTICE; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PALPATION; PRIVATE PRACTICE; PROSTATE; PROSTATIC NEOPLASMS; UNITED STATES; UROLOGY;

EID: 0032006961     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00620-1     Document Type: Article

References (41)

1. Wingo PA, Landis S, Ries LAG. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin. 47:1997;239-242.
2. Allhoff E, de Riese W, Eifinger M, Pethke J, Jonas U. Prostate specific antigen comparative clinical appreciation of serodiagnostic measure after 8 years of experience. World J Urol. 7:1989;12-16.
3. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 143:1990;1146-1152.
4. Jacobson SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, Chute CG, Leiber MM. Incidence of prostate cancer diagnosis in eras before and after serum prostate specific antigen testing. JAMA. 274:1995;1445-1449.
5. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 152:1994;1358-1368.
6. Babian JR, Kojima M, Ramirez EI, Johnston D. Comparative analysis of prostate specific antigen and its indexes in detection of prostate cancer. J Urol. 156:1996;432-437.
7. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol. 157:1997;1315-1321.
8. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in pathological features and prognosis of patients treated with radical prostatectomy? J Urol. 157:1997;2212-2218.
9. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol. 157:1997;2206-2209.
10. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374.
11. Epstein JI. Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease? Semin Urol Oncol. 157:1996;165-173.
12. Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol. 155:1996;821-826.
13. Elgamal AA, VanPoppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol. 157:1997;244-250.
14. Harris CH, Dalkin BL, Martin E, Marx PC, Ahmann FR. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/ml or less. J Urol. 157:1997;1740-1743.
15. Noldus J, Stamey TA. Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4.0 ng/ml or less. J Urol. 155:1996;441-443.
16. American Cancer Society - Facts and Figures. 1997;. http://www.cancer.org/statistics/97 cff/97prosta.html.
17. Terris MK, Haney KJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 45:1995;75-80.
18. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA. 275:1996;288-294.
19. Epstein JI, Pizov G, Walsh PC. Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer. 71:1993;3582-3593.
20. Orozco R, Schwob V, Bassler T, Egan A, O'Dowd G, Bostwick D. The diagnosis of "suspicious" for adenocarcinoma in prostate biopsies: evaluation of follow-up biopsies. (abstract) Mod Pathol. 10:1997;84A.
21. Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies. (abstract) Mod Pathol. 10:1997;70A.
22. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, O'Dowd GJ, Veltri RW. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with PSA level. J Urol. 156:1996;1375-1380.
23. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE. Update on the appropriate staging evaluation for newly diagnosed prostate cancer: update 1997. J Urol. 158:1997;687-698.
24. Dietrick DD, McNeal JE, Stamey TA. Core cancer length in ultrasound-guided systematic sextant biopsies: a pre-operative evaluation of prostate cancer volume. Urology. 157:1995;987-992.
25. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 156:1996;1059-1063.
26. Karakiewicz PI, Bazinet M, Aprikian AG, Trudel C, Aronson S, Nachabe M, Peloquint F, Dessureault J, Goyal MS, Begin LR, Elhilali MM. Outcome of sextant biopsy according to gland volume. Urology. 49:(1):1997;55-59.
27. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 150:1993;110-114.
28. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 142:1989;71-74.
29. Hammerer P, Huland H. Systematic sextant biopsies of 651 patients referred for prostate evaluation. J Urol. 151:1994;99-102.
30. Stamey TA. Making the most out of six systematic sextant biopsies. Urology. 45:1995;2-12.
31. D'Amico AV, Chang H, Holupka E, Renshaw A, Desjarden A, Chen M, Loughlin KR, Richie JP. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology. 49:1997;385-391.
32. Chen ME, Troncoso P, Johnston DA, Tang K, Babaian RJ. Optimization of prostate biopsy strategy using computer based analysis. J Urol. 158:1997;2168-2175.
33. Shrader-Bogan CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer. 79:1997;1977-1986.
34. Chodak GW. The role of conservative management in localized prostate cancer. Cancer. 74:1994;2178-2181. (7 Suppl).
35. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results of ten years. J Urol. 152:1994;1831-1836. (5 Pt 2).
36. Catalona WJ. Management of cancer of the prostate. N Engl J Med. 331:1994;996-1004.
37. Bostwick DG, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol. 154:1995;1791-1794.
38. Sakr KW, Grignon DJ, Vanlue C, Crissman JD. Analysis of 3300 consecutive prostate biopsies: a 4-year institutional experience with the frequency of carcinoma, isolated high grade prostatic intraepithelial neoplasia and "atypical" (abstract) Mod Pathol. 10:1997;79A.
39. Wills ML, Hamper UM, Epstein JI. The incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsies. (abstract) J Urol. 157:1997;229.
40. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56:1996;3091-3102.
41. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol. 148:1992;829-832.